Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Burning Rock Biotech stock | $13.18

Learn how to easily invest in Burning Rock Biotech stock.

Burning Rock Biotech Limited is a diagnostics & research business based in the US. Burning Rock Biotech shares (BNR) are listed on the NASDAQ and all prices are listed in US Dollars. Burning Rock Biotech employs 938 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Burning Rock Biotech

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BNR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Burning Rock Biotech stock price (NASDAQ: BNR)

Use our graph to track the performance of BNR stocks over time.

Burning Rock Biotech shares at a glance

Information last updated 2021-10-17.
Latest market close$13.18
52-week range$14.92 - $39.75
50-day moving average $18.33
200-day moving average $25.10
Wall St. target price$32.72
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.17

Buy Burning Rock Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Burning Rock Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Burning Rock Biotech price performance over time

Historical closes compared with the close of $13.18 from 2021-10-21

1 week (2021-10-15) -8.22%
1 month (2021-09-22) -35.30%
3 months (2021-07-22) -52.07%
6 months (2021-04-22) -54.25%
1 year (2020-10-22) -54.46%
2 years (2019-10-18) N/A
3 years (2018-10-18) N/A
5 years (2016-10-18) N/A

Burning Rock Biotech financials

Revenue TTM $489.5 million
Gross profit TTM $313.9 million
Return on assets TTM -14.91%
Return on equity TTM -27.13%
Profit margin -134.56%
Book value $20.88
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting Burning Rock Biotech shares

There are currently 1.7 million Burning Rock Biotech shares held short by investors – that's known as Burning Rock Biotech's "short interest". This figure is 32% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Burning Rock Biotech shares can be evaluated.

Burning Rock Biotech's "short interest ratio" (SIR)

Burning Rock Biotech's "short interest ratio" (SIR) is the quantity of Burning Rock Biotech shares currently shorted divided by the average quantity of Burning Rock Biotech shares traded daily (recently around 280818.13804173). Burning Rock Biotech's SIR currently stands at 6.23. In other words for every 100,000 Burning Rock Biotech shares traded daily on the market, roughly 6230 shares are currently held short.

However Burning Rock Biotech's short interest can also be evaluated against the total number of Burning Rock Biotech shares, or, against the total number of tradable Burning Rock Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Burning Rock Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Burning Rock Biotech shares in existence, roughly 20 shares are currently held short) or 0.0522% of the tradable shares (for every 100,000 tradable Burning Rock Biotech shares, roughly 52 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Burning Rock Biotech.

Find out more about how you can short Burning Rock Biotech stock.

Burning Rock Biotech share dividends

We're not expecting Burning Rock Biotech to pay a dividend over the next 12 months.

Have Burning Rock Biotech's shares ever split?

Burning Rock Biotech's shares were split on a 1:3 basis on 31 July 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Burning Rock Biotech shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Burning Rock Biotech shares which in turn could have impacted Burning Rock Biotech's share price.

Burning Rock Biotech overview

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene.

Frequently asked questions

What percentage of Burning Rock Biotech is owned by insiders or institutions?
Currently 0.139% of Burning Rock Biotech shares are held by insiders and 49.672% by institutions.
How many people work for Burning Rock Biotech?
Latest data suggests 938 work at Burning Rock Biotech.
When does the fiscal year end for Burning Rock Biotech?
Burning Rock Biotech's fiscal year ends in December.
Where is Burning Rock Biotech based?
Burning Rock Biotech's address is: Building 3, Standard Industrial Unit 2, Guangzhou, China, 510005
What is Burning Rock Biotech's ISIN number?
Burning Rock Biotech's international securities identification number is: US12233L1070

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site